POSITION SUMMARY:

We are seeking a Principal Clinical Scientist / Associate Director of Real-World Evidence & Epidemiology to drive observational evidence strategy for our Early Cancer Detection (ECD) portfolio. Population-scale liquid biopsy screening requires robust real-world evidence demonstrating clinical utility, clinical decision-making impact, and downstream patient outcomes. This ownership role uses real-world datasets to accelerate standard-of-care implementation across oncology diagnostics. Working with a builder mindset, you will partner across Clinical Science, Medical Affairs, Market Access, and Data Science to convert population-scale observational data into actionable clinical implementation strategies.

PRIMARY RESPONSIBILITIES:

Epidemiology and Observational Research Strategy

• Lead the design, protocol development, and execution of prospective observational studies, registries, and retrospective database assessments across early cancer detection programs
• Shape post-market evidence generation strategies by isolating critical clinical utility and implementation hurdles that can be resolved via real-world data assets
• Translate clinical and market requirements into rigorous, practical study designs, specifying target populations, clinical endpoints, and analytic frameworks
• Systematically identify and mitigate sources of bias, confounding factors, and missing data variance inherent in real-world healthcare datasets
• Design protocols evaluating clinical utility across diverse populations, ensuring the data generated directly supports precision interventions for individual patients and families

Cross-Functional Scientific Leadership

• Partner across Clinical Science, Medical Affairs, Product Management, and Market Access to prioritize evidence generation initiatives based on regulatory and clinical urgency
• Collaborate with Biostatistics and Data Science to engineer statistical analysis plans, interpret data findings, and deliver clinical contextualization
• Extract empirical evidence from early commercial and Laboratory Developed Test (LDT) cohorts to isolate adoption variables, diagnostic compliance, and real-world clinical workflows
• Deliver real-world data assets that dismantle payer coverage barriers and ground product positioning strictly in clinical utility metrics

Evidence Dissemination and External Engagement

• Convert complex epidemiological findings into clear, high-integrity scientific narratives for internal product governance and external healthcare stakeholders
• Spearhead the development of peer-reviewed abstracts, posters, presentations, and core manuscripts for major oncology and diagnostic conferences
• Engage with external clinical collaborators, investigators, and key opinion leaders (KOLs) to advance the platform base for early cancer detection

QUALIFICATIONS:

• Advanced degree (PhD, MPH, MS, PharmD, or equivalent scientific credential) in epidemiology, health outcomes research, biostatistics, or a highly quantitative field
• 7+ years of experience leading real-world evidence generation, observational clinical research, or HEOR portfolios within the life sciences industry
• Documented experience executing observational studies across the entire asset lifecycle, from initial protocol drafting through statistical analysis and publication
• Deep data competency across real-world data sources, including longitudinal medical claims, electronic health records (EHR), and clinical registries
• Direct experience in oncology clinical trials, molecular diagnostics, or early cancer detection programs is preferred

KNOWLEDGE, SKILLS, AND ABILITIES:

• Take full ownership of complex clinical portfolios as an autonomous strategist
• Rigorous analytical skills with the ability to pressure-test study assumptions and ground major milestones entirely in data
• Communicate with technical precision across matrixed lines to align R&D, commercial, medical, and lab operations functions
• Strong ownership mindset with the capability to balance scientific rigor, speed, and trial resource constraints under tight timelines
• Comfort with ambiguity and an evolving product surface as underlying genomic science advances